摘要
钙结合蛋白S100B作为多种疾病的生物标志物备受关注,S100B蛋白主要表达于神经胶质细胞,通过细胞内和细胞外的信号转导通路起作用。S100B蛋白的生物学作用与浓度和生理状态密切相关,释放的S100B与晚期糖基化终产物受体相关并且诱导了多种细胞信号转导的起始点。据说S100B生物活性的调节是通过磷脂酰肌醇3激酶/ Akt,p53,丝裂原活化蛋白激酶,包括核因子-kappaB和环磷酸腺的转录因子来实现的。血液中S100B的水平能预测多种疾病的进展或预后,如脑血管疾病,神经退行性疾病,运动神经元疾病,创伤性脑损伤,精神分裂症,抑郁症,糖尿病,心肌梗塞,癌症和传染病等。鉴于S100B的活动与这些疾病的病理过程相关,S100B不应该被简单地视为一种生物标志物,它可以作为对这些疾病的治疗目标。进一步阐明S100B的作用以制定多种疾病创新的治疗策略。
关键词: RAGE;PI3K;MAPK;神经退行性疾病;中风;糖尿病;生物标志物。
Current Medicinal Chemistry
Title:Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Volume: 23 Issue: 15
Author(s): Zhao Zhong Chong, Benjarat Changyaleket, Haoliang Xu, Randy O. Dull, David E. Schwartz
Affiliation:
关键词: RAGE;PI3K;MAPK;神经退行性疾病;中风;糖尿病;生物标志物。
摘要: The calcium binding protein S100B has attracted great attention as a biomarker for a variety of diseases. S100B is mainly expressed in glial cells and functions through intracellular and extracellular signaling pathways. The biological roles of S100B have been closely associated with its concentrations and its physiological states. The released S100B can bind to the receptor of advanced glycation end products and induce the initiation of multiple cell signaling transductions. The regulation of S100B bioactivities has been suggested through phosphoinositide 3 kinase/Akt, p53, mitogen-activated protein kinases, transcriptional factors including nuclear factor-kappaB, and cyclic adenosine monophosphate. The levels of S100B in the blood may function to predict the progress or the prognosis of many kinds of diseases, such as cerebrovascular diseases, neurodegenerative diseases, motor neuron diseases, traumatic brain injury, schizophrenia, depression, diabetes mellitus, myocardial infarction, cancer, and infectious diseases. Given that the activity of S100B has been implicated in the pathological process of these diseases, S100B should not be simply regarded as a biomarker, it may also function as therapeutic target for these diseases. Further elucidation of the roles of S100B may formulate innovative therapeutic strategies for multiple diseases.
Export Options
About this article
Cite this article as:
Zhao Zhong Chong, Benjarat Changyaleket, Haoliang Xu, Randy O. Dull, David E. Schwartz , Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases, Current Medicinal Chemistry 2016; 23 (15) . https://dx.doi.org/10.2174/0929867323666160406121117
DOI https://dx.doi.org/10.2174/0929867323666160406121117 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Melatonin Receptor as a Drug Target for Neuroprotection
Current Molecular Pharmacology Cardiac Amyloidosis Responding to Bortezomib: Case Report and Review of Literature
Current Cardiology Reviews Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design Astrocytes and Inflammasome: A Possible Crosstalk in Neurological Diseases
Current Medicinal Chemistry Metal Toxicity and Speciation: A Review
Current Medicinal Chemistry Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled
Current Molecular Pharmacology Associations of Cerebrovascular and Alzheimer’s Disease Pathology with Brain Atrophy
Current Alzheimer Research Decoupling of N-Acetyl-Aspartate and Glutamate Within the Dorsolateral Prefrontal Cortex in Schizophrenia
Current Molecular Medicine Intravitreal Triamcinolone for the Treatment of Diabetic Macular Edema
Current Diabetes Reviews Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology Statins and epilepsy: preclinical studies, clinical trials and statin-anticonvulsant drug interactions
Current Drug Targets CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study
Current Alzheimer Research Outcome of Newborns with Neonatal Seizures: Risk Factors and Predictors
Current Pediatric Reviews Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism Study on Utilization of Detoxified Jatropha curcas Seed Cake Subjected to Solid State Fermentation as a Dietary Supplement in Wistar Rats
Recent Patents on Food, Nutrition & Agriculture Preparation and Chemical Characterization of Eco-friendly ORMOSIL Nanoparticles of Potential Application in DNA Gene Therapy
Current Nanoscience A New Target for Diagnosis and Treatment of CNS Disorders: Agmatinergic System
Current Medicinal Chemistry Clinical Pharmacology of Novel Anti-Alzheimer Disease Modifying Medications
Current Topics in Medicinal Chemistry Berberine Ameliorates Cognitive Impairment by Regulating Microglial Polarization and Increasing Expression of Anti-inflammatory Factors following Permanent Bilateral Common Carotid Artery Occlusion in Rats
CNS & Neurological Disorders - Drug Targets Restoring Cortical Connectivity Directionality and Synchronization is Essential to Treating Disorder of Consciousness
Current Pharmaceutical Design